Across the drug development lifecycle, including pre-IND readiness, early clinical transitions, manufacturing evolution, and regulatory engagement, biotech and pharmaceutical companies turn to Arc Nouvel for specialized guidance. In oncology and beyond, the firm’s clients are often navigating early clinical decisions that will quietly determine the fate of entire programs years later. Yet an equally important question often arises: who are the experts behind Arc Nouvel, and what perspective shapes their guidance when the stakes are highest?
Among the firm’s consultants is Vivian Li, Ph.D., MBA, a biopharma strategist whose professional path reflects the increasingly interconnected reality of modern drug development. With experience spanning academic research, big pharma R&D, venture investment, and business development, Dr. Li brings a vantage point that few early-stage companies can replicate internally. Her work sits at a critical junction where scientific promise must withstand regulatory scrutiny, commercial reality, and capital discipline simultaneously.
In this article, we will explore Dr. Li’s career journey and share her insights on how strategic clarity, not just scientific progress, ultimately determines clinical and enterprise success.
Expanding the Definition of Risk
Dr. Li’s early career followed a rigorous scientific trajectory. After earning her PhD in biomedical sciences and completing postdoctoral training at the University of Pennsylvania, she joined GlaxoSmithKline (GSK), where she gained hands-on experience in drug discovery, IND-enabling work, and biomarker-driven development.
At that stage, her understanding of risk was grounded largely in biological uncertainty.
“Earlier in my career, risk meant mainly scientific uncertainty, does the biology make sense, does the mechanism work,” she recalls.
The turning point came when she transitioned into early-stage biotech investment and business development. In that environment, promising science frequently encountered a different kind of reality check. Programs that looked compelling in the laboratory sometimes struggled to attract capital or partnerships, while others with more modest biology advanced because their development strategy was sharper and more coherent.
“Working across academia, pharma, R&D, and venture investment fundamentally changed how I think about risk and value creation,” Dr. Li explains.
Today, her definition of risk is deliberately multidimensional.
“It includes the scientific risk, but also the regulatory risk, execution risk, and strategic risk,” she says.
This broader lens has shaped how she now advises emerging companies. In her view, generating more data does not automatically reduce the uncertainties that matter most to investors, regulators, or potential partners. Programs can advance technically while accumulating hidden fragility in their strategic positioning.
“A program can be scientifically sound but still fail if it doesn’t answer the right question for the regulators, partners, or investors at the right time,” she adds.
We Need to Generate Decision-Relevant Data
Across her advisory work, Dr. Li has observed a pattern that rarely surfaces in formal post-mortems. When early clinical programs struggle, the explanation is often framed as biological failure or competitive pressure. More often, she believes, the underlying issue is that development was approached too narrowly as a technical exercise.
“Most of the mistakes are not technical, they are strategic,” she says.
In practical terms, this frequently begins with trial design. Many teams, particularly those led by deeply scientific founders, build studies to answer mechanistic questions without fully mapping how those answers will support regulatory positioning, commercial differentiation, or future partnering discussions. The science progresses, but the investment narrative remains underdeveloped.
“Companies sometimes treat early clinical development as purely a technical exercise,” Dr. Li observes. “But the trial needs to answer commercial and regulatory questions as well.”
Over time, this disconnect can quietly constrain strategic flexibility. What initially appears to be thorough scientific exploration can later become a structural limitation that is expensive to unwind. From her vantage point, the most effective development plans begin not with the experiment itself but with clarity about which future decision the data must enable.
“Value is not created simply by generating data, we need to generate decision-relevant data,” she emphasizes.
Good Science is Not Enough
First-time biotech founders often encounter these dynamics most acutely. Many bring strong scientific conviction and encouraging preclinical signals, but fewer fully anticipate how early clinical decisions shape long-term optionality and enterprise positioning.
“They focus heavily on the scientific part but do not always have the bigger picture about the later market or commercial part,” Dr. Li says.
One recurring pattern she observes is overconfidence in early datasets that appear compelling within the laboratory context but have not yet been pressure-tested against regulatory expectations or competitive benchmarks. Another is the persistent belief that strong science alone will attract capital.
“Some founders think good science will automatically attract partnership or capital, which is not always right,” she notes.
From the investment side, she has seen technically credible programs struggle because the development narrative lacked coherence or differentiation. Investors were not questioning the biology; they were questioning the pathway to value creation.
Her role, increasingly, is to help leadership teams zoom out early enough to preserve strategic flexibility before key decisions become locked in.
Generating Decision-Grade Data
Even within experienced organizations, misalignment between scientific and business teams remains one of the most persistent sources of hidden risk. Each function optimizes for rational but different success metrics. Scientists prioritize mechanistic clarity and experimental rigor. Business leaders focus on speed, capital efficiency, and market positioning. Clinical teams emphasize patient relevance and operational feasibility.
“The misalignment happens when their goals are not integrated into a shared development strategy,” Dr. Li explains.
Left unaddressed, these differences rarely produce open conflict. Instead, they manifest as subtle drift: protocols become more complex than necessary, timelines compress in ways that create regulatory friction, or datasets emerge that are technically sound but strategically ambiguous.
“Scientists may design beautiful studies that are not decision-relevant, while business teams may push their timeline and compromise data quality or regulatory credibility,” she says.
The downstream consequences are measurable, extended burn, delayed inflection points, and reduced probability of success. For Dr. Li, the remedy begins with a disciplined reframing of what clinical development is meant to produce.
“Clinical development is not only generating data, it is generating decision-grade data,” she emphasizes.
Speed vs Quality
Few pressures shape early-stage biotech behavior more strongly than the perceived need to move quickly. Limited runway and competitive landscapes create a powerful incentive to accelerate. Dr. Li does not dismiss that reality, but she is cautious about speed pursued without strategic clarity.
“The key is not simply choosing between speed or data quality,” she says. “It is being very clear about where the strategic decision we want to make.”
When that decision target is explicit, whether enabling fundraising, supporting partnership discussions, or preparing for regulatory engagement, development plans tend to become more focused and capital efficient. Speed becomes purposeful rather than reactive.
She is particularly wary of what she calls false efficiency.
“Fast data sometimes does not answer future stakeholders’ questions and can create false efficiency and later costly redesign,” she warns.
At the same time, she cautions against the opposite extreme. Over-engineering early trials in pursuit of theoretical completeness can quietly consume scarce capital without meaningfully improving decision quality. The optimal balance, she argues, lies in what she describes as strategic efficiency: generating enough depth to unlock the next value inflection point while preserving flexibility for what follows.
The Questions That Should Come Earlier
If there is a moment where strategic clarity matters most, Dr. Li believes it comes just before first-in-human studies begin. By that point, internal enthusiasm is often high and momentum strong, yet foundational questions frequently remain underdeveloped.
Among the most critical are deceptively simple: What is the true target product profile? Who is the real decision-maker for this asset? How will the program be meaningfully differentiated in three years, not just today?
“Many companies enter the clinic with a strong scientific hypothesis but without a clear long-term development narrative,” she says.
The consequences of that gap often appear only when external stakeholders begin asking harder questions.
“This gap usually becomes visible only when they start talking to regulators or investors,” Dr. Li notes.
By then, key design decisions, dose, population, endpoints, may be difficult or costly to revisit.
Knowing When to Stop
Among the most emotionally difficult decisions in drug development is the decision to stop. Scientific teams and founders naturally develop attachment to programs that have consumed years of effort and capital. Yet Dr. Li has come to view disciplined stopping as one of the highest-value strategic capabilities a company can build.
She encourages leadership teams to reframe pivotal inflection points as capital allocation decisions rather than scientific judgments.
“The question is not simply whether the science is interesting,” she says. “It is whether this is the best use of limited resources, time, capital, and organizational focus.”
From a portfolio perspective, continuing a marginal program carries real opportunity cost. Resources committed to one asset are resources unavailable to another potentially higher-probability opportunity.
“In many cases, the value of the decision is not only optimizing a single program but improving the overall portfolio,” she explains.
Her conclusion is characteristically direct.
“Knowing when to stop has much more power than knowing how to continue.”
What Makes a Program Investable
Dr. Li’s time in venture investment has given her a clear view of how external stakeholders evaluate clinical assets. Positive efficacy signals, while necessary, rarely determine investment decisions on their own.
“I think positive efficacy is only the starting point,” she says.
Investors and partners, she explains, are evaluating coherence across multiple dimensions: unmet medical need, strength of differentiation, regulatory plausibility, and — critically — the credibility of the long-term development narrative.
“They are looking for assets that tell a clear story — what is the mechanism, what is the indication, how the program evolves over time, and what is the realistic pathway to create value,” Dr. Li explains.
Her work often focuses on shaping clinical strategy so that the data package naturally supports that story rather than forcing teams to retrofit a narrative later.
Acting as a Strategic Translator Between Science, Business, and Capital
Within Arc Nouvel’s multidisciplinary team, Dr. Li sees her distinctive contribution as helping companies connect clinical execution directly to enterprise value creation. Where traditional clinical experts may focus primarily on how to design and run trials, her work centers on why specific decisions matter financially and strategically.
“My unique contribution is helping clients connect preclinical and clinical development directly to enterprise value,” she explains.
Drawing on her background across pharma R&D, venture investment, and business development, she often helps leadership teams evaluate programs at the portfolio level and prioritize based on risk-adjusted value.
“I help leadership teams think at the portfolio level and design clinical plans that generate decision-driven data rather than just technically correct data,” she says.
At its core, the role is one of alignment across domains that rarely sit comfortably together.
“To act as a strategic translator between science, business, and capital,” Dr. Li summarizes.
Direction Before Velocity
As the conversation closes, Dr. Li returns to the principle that quietly anchors her entire framework: clarity of direction must precede acceleration.
“Planning earlier saves a lot of time and energy,” she reflects.
Her warning to biotech leaders is simple but consequential.
“If you go faster toward the wrong direction, you need to go back, and that is very costly.”
For companies navigating the uncertainty of early clinical development, that distinction can determine whether promising science matures into a viable therapy or stalls under the weight of avoidable misalignment. In Dr. Li’s view, the future of successful drug development will belong not simply to those who move fastest, but to those who integrate most thoughtfully across science, strategy, and capital from the very beginning.
Why Arc Nouvel?
Dr. Li’s decision to join Arc Nouvel reflects this same strategic orientation. In a consulting landscape often dominated by execution-focused providers, she was drawn to what she describes as the firm’s strategy-first philosophy.
“Strategy first, but not execution first, that is very important,” she says.
Traditional CRO models frequently begin with operational questions. Arc Nouvel, in her experience, begins one level higher.
“The firm starts with the question of what is the optimal development path for the specific company,” she explains.
That integrated approach, combining scientific, regulatory, operational, and commercial thinking, strongly aligns with how she now views modern clinical development.
Another reason to join was the team.
“I know our team is excellent. Dr. Ibrahim is excellent. Everyone is great.”
